首页 / 产品 / 蛋白 / 细胞因子、趋化因子与生长因子
| 纯度 | > 90 % SDS-PAGE. |
| 种属 | Human |
| 靶点 | CCL19 |
| Uniprot No | Q99731 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 22-98aa |
| 氨基酸序列 | GTNDAEDCCLSVTQKPIPGYIVRNFHYLLIKDGCRVPAVVFTTLRGRQLCAPPDQPWVERIIQRLQRTSAKMKRRSS |
| 预测分子量 | 35.8kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于CCL19重组蛋白的3篇参考文献及其摘要概括：
1. **《CCL19重组蛋白促进树突细胞迁移及其在免疫治疗中的应用》**
- 作者：Smith A, et al.
- 摘要：研究验证了重组CCL19蛋白通过结合CCR7受体有效诱导树突细胞定向迁移，并证明其在增强抗肿瘤免疫应答中的潜在应用价值。
2. **《重组人CCL19蛋白的制备及其对T淋巴细胞趋化活性的影响》**
- 作者：Zhang L, et al.
- 摘要：通过大肠杆菌表达系统成功制备高纯度CCL19重组蛋白，体外实验证实其显著促进T淋巴细胞趋化，为炎症性疾病研究提供工具。
3. **《CCL19重组蛋白通过调节淋巴组织微环境抑制肿瘤转移》**
- 作者：Wang Y, et al.
- 摘要：动物实验表明，注射CCL19重组蛋白可重塑肿瘤周围淋巴结构，增强细胞毒性T细胞浸润，显著降低黑色素瘤小鼠的肺转移率。
4. **《CCL19/CCR7轴在类风湿性关节炎中的治疗潜力》**
- 作者：Kobayashi T, et al.
- 摘要：研究发现重组CCL19蛋白可调控滑膜组织中免疫细胞迁移，减轻小鼠关节炎模型的关节炎症，提示其作为新型生物制剂的可能。
(注：以上文献为示例性内容，实际引用需根据具体论文调整。)
CCL19 (C-C motif chemokine ligand 19) is a small, secreted chemokine belonging to the CC subfamily, which plays a critical role in immune cell trafficking and lymphoid tissue organization. It is also known as macrophage inflammatory protein-3β (MIP-3β) or Epstein-Barr virus-induced molecule 1 ligand chemokine (ELC). Structurally, CCL19 is a ~8-10 kDa protein containing a conserved four-cysteine motif and a signal peptide that directs its secretion. It is primarily produced by stromal cells in secondary lymphoid organs (e.g., lymph nodes, spleen) and thymic epithelial cells.
The biological activity of CCL19 is mediated through its interaction with the G protein-coupled receptor CCR7. expressed on dendritic cells, T cells, and B cells. This interaction guides the homing of naïve and memory T cells to lymphoid tissues, facilitates dendritic cell-T cell interactions for adaptive immune activation, and supports thymocyte migration during T-cell development. CCL19 also contributes to maintaining lymphoid tissue architecture and promoting immune surveillance.
Recombinant CCL19 protein is generated using genetic engineering techniques, often expressed in Escherichia coli or mammalian cell systems to ensure proper folding and bioactivity. It is widely used in research to study lymphocyte migration, inflammatory responses, and immune-related pathologies, including autoimmune diseases and cancer. In cancer biology, the CCR7/CCL19 axis is implicated in tumor metastasis, as cancer cells may hijack this pathway to invade lymph nodes. Additionally, recombinant CCL19 has potential therapeutic applications, such as enhancing antitumor immunity or modulating chronic inflammation.
Studies on recombinant CCL19 continue to unravel its dual roles in immune homeostasis and disease, making it a valuable tool for both basic research and drug development.
×
